CRVO•benzinga•
CervoMed's Dementia Study's 16-Week Data 'Compelling Enough To Move From Sidelines' Analyst Says
Summary
CervoMed's Phase 2b study extension shows improved cognitive outcomes with neflamapimod, leading to an analyst upgrade and increased confidence in the drug.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 13, 2025 by benzinga